Accessibility Menu
Rvl Pharmaceuticals Plc logo

Rvl Pharmaceuticals Plc(OTC) RVLPQ

Market Cap$100.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2018)-100%
5 Year-100%
1 Year+0%
1 Month+0%
$0.00
+0.00%
+0.00Today
Rvl Pharmaceuticals Plc last closing stock price
MetricPriceDate
Last closeUSD 0.002026-08-05
Rvl Pharmaceuticals Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-07-27
1 month+0%USD 0.002026-07-02
3 month+0%USD 0.002026-05-07
Year to date+0%USD 0.002025-12-31
1 year+0%USD 0.002025-08-04
3 year-100%USD 0.472023-08-04
5 year-100%USD 3.802021-08-06
Since inception-100%USD 8.152018-10-18

Rvl Pharmaceuticals Plc Financials at a Glance

Market Cap

$100.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$36.92M

Net Income (TTM)

-$68.27M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

8.93 (High)

Price

$0.00

Volume

1

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

Aug 10, 2026

RVLPQ News

GettyImages-1200771188

Why Osmotica Pharmaceuticals Stock Plunged Today

Prosper Junior BakinyDec 30, 2020
GettyImages-1081842890

Why Osmotica Pharmaceuticals Is Plunging Today

Prosper Junior BakinyJul 14, 2020
GettyImages-1017183520

Why Osmotica Pharmaceuticals Jumped Today

Prosper Junior BakinyJul 10, 2020
getty-woman-looking-pills-2

These 2 Pharma Stocks Could Be Top Stocks in 2020

Amar KhatriJul 6, 2020

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Rvl Pharmaceuticals Plc

RVL Pharmaceuticals plc is a specialized drug company focused on developing and marketing innovative pharmaceutical solutions for unmet needs in the ophthalmic and medical aesthetics sectors. The company operates primarily in the United States, Argentina, and Hungary, with its flagship product, Upneeq, designed to treat acquired blepharoptosis in adults.

Products and Services
  • Upneeq (RVL-1201), an ophthalmic solution for drooping eyelids
  • Research and development of additional ophthalmic and aesthetic products
  • Marketing and distribution across multiple international markets
Growth Outlook
  • Recent quarterly revenue of $8.26 million indicates strong market demand
  • Continued investment in R&D to expand product offerings
  • Strategic focus on international markets to drive growth
Financial Highlights
  • Trailing twelve months revenue of $35.5 million reflects consistent sales performance
  • Cash and cash equivalents of $19.16 million as of June 30, 2023
  • Gross profit margin of 76.4% in Q2 2023 demonstrates effective cost management
RVL Pharmaceuticals plc is positioned in a niche market with significant growth potential. The company's focus on innovative solutions for unmet medical needs, particularly in ophthalmology, sets it apart in the biotechnology sector. The recent revenue figures suggest a solid demand for Upneeq, while the strong gross profit margin indicates effective operational efficiency. With a commitment to research and development, RVL Pharmaceuticals aims to expand its product portfolio and enhance its market presence, making it an intriguing option for investors interested in the biotechnology field.
AI Generated • Jul 31, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

125

CEO

Brian A. Markison, CPA

Website

www.rvlpharma.com

Headquarters

Bridgewater, NJ 08807, US

RVLPQ Financials

Key Financial Metrics (TTM)

Gross Margin

80.98%

Operating Margin

-91.87%

Net Income Margin

-103.96%

Return on Equity

-80.88%

Return on Capital

-42.07%

Return on Assets

-40.22%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$100.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

111.41M

Volume

1

Avg. Volume

11.87K

Financials (TTM)

Gross Profit

$27.59M

Operating Income

-$57.47M

EBITDA

-$30.61M

Operating Cash Flow

-$44.41M

Capital Expenditure

-$3.08M

Free Cash Flow

-$47.49M

Cash & ST Invst.

$19.16M

Total Debt

$58.15M

Rvl Pharmaceuticals Plc Performance Analysis

Rvl Pharmaceuticals Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 17,501,000N/A
20222022-12-31USD 49,721,000184.1%
Rvl Pharmaceuticals Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32022-09-3018.6%
Q42022-12-31-2.1%
Q12023-03-31-9.9%
Q22023-06-30-6.5%
Rvl Pharmaceuticals Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -1.02N/A
20222022-12-31USD -0.58-43.8%
Rvl Pharmaceuticals Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32022-09-30-14.3%
Q42022-12-31-12.5%
Q12023-03-3133.3%
Q22023-06-30-100.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2023YOY CHG

Revenue

$8.26M

-2.2%

Gross Profit

$6.31M

+1.5%

Gross Margin

76.43%

N/A

Market Cap

$100.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$0.80

N/A

Employees

125

N/A

Net Income

-$23.89M

-97.3%

EBITDA

-$371.00K

+96.9%

Quarterly Fundamentals

Name
Q2 2023YOY CHG

Total Cash

$19.16M

-32.9%

Total Debt

$58.15M

+30.9%

Accounts Receivable

$1.93M

+5.4%

Inventory

$1.36M

+156.8%

Long Term Debt

$192.00K

-99.6%

Short Term Debt

$57.96M

+4896.1%

Return on Assets

-40.22%

N/A

Return on Invested Capital

-41.99%

N/A

Free Cash Flow

-$13.11M

-756.7%

Operating Cash Flow

-$12.06M

-704.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
VSMDVasamed, Inc.
$0.00+0.00%
TRVNTrevena, Inc.
$0.00-90.99%
RCARRenovaCare, Inc.
$0.00+0.00%
GNLKQGeneLink, Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$114.92+0.06%
NVDANvidia
$218.99-0.00%
TTDThe Trade Desk
$17.67-0.07%
SOUNSoundHound AI
$7.08+0.10%

Questions About RVLPQ

What is the current price of Rvl Pharmaceuticals Plc?

Rvl Pharmaceuticals Plc is trading at $0.00 per share.

What is the 52-week range for Rvl Pharmaceuticals Plc?

Over the past 52 weeks, Rvl Pharmaceuticals Plc has traded between $0.00 and $0.00.

How much debt does Rvl Pharmaceuticals Plc have?

As of the most recent reporting period, Rvl Pharmaceuticals Plc reported total debt of $57.49M.

How much cash does Rvl Pharmaceuticals Plc have on hand?

Rvl Pharmaceuticals Plc reported $44.54M in cash and cash equivalents in its most recent financial results.

What is Rvl Pharmaceuticals Plc’s dividend yield?

Rvl Pharmaceuticals Plc does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services